Property and casualty insurers, as well as life insurers, are expected to benefit from Donald Trump's presidential election ...

Evercore ISI analyst Liisa Bayko upgraded Editas Medicine (EDIT) to Outperform from In Line with a price target of $7, up from $3. Editas has ...

The president and CEO of Evercore Wealth Management and Evercore Trust explains how he built a business to serve the complex ...

Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss Amazon ahead of earnings.

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), ...

Proxies for former President Donald Trump's trade policies — specifically bitcoin and the Chinese yuan — can help gauge what market participants are making of the election results, Julian Emanuel, ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Overall, the bull market “looks to remain intact,” Evercore’s team emphasizes. However, it adds that the S&P 500 index has the potential for a post-election “meltup” to 6,500 or experience a sell-off.

Evercore ISI analyst Kirk Materne highlighted multiple positives in Microsoft's report, including 16% constant-currency revenue growth for Microsoft 365 Commercial and increasing contributions from ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

The ride-hailing pioneer is contending with slowing bookings growth, rising insurance costs and an alliance between DoorDash ...